PTX3 and metabolic dysfunction-associated steatotic liver disease: This finding aligns with previous reports linking elevated serum PTX3 levels to type 2 diabetes in obese patients with nonalcoholic fatty liver disease, indicating the clinical relevance of PTX3 in metabolic disorders (Karamfilova et al., 2022, Trojak et al., 2019).